| scholarly article | Q13442814 |
| P50 | author | Kay Davies | Q6380176 |
| P2093 | author name string | Michihiro Imamura | |
| Eijiro Ozawa | |||
| Mikiharu Yoshida | |||
| Michiko Ishikawa-Sakurai | |||
| P433 | issue | 7 | |
| P304 | page(s) | 693-702 | |
| P577 | publication date | 2004-02-12 | |
| P1433 | published in | Human Molecular Genetics | Q2720965 |
| P1476 | title | ZZ domain is essentially required for the physiological binding of dystrophin and utrophin to beta-dystroglycan | |
| P478 | volume | 13 |
| Q39278570 | ABC of multifaceted dystrophin glycoprotein complex (DGC). |
| Q37109015 | Assessment of the structural and functional impact of in-frame mutations of the DMD gene, using the tools included in the eDystrophin online database |
| Q36506919 | Autologous skeletal muscle derived cells expressing a novel functional dystrophin provide a potential therapy for Duchenne Muscular Dystrophy |
| Q37085050 | Biology of the striated muscle dystrophin-glycoprotein complex |
| Q90912850 | Breakpoint junction features of seven DMD deletion mutations |
| Q36402509 | Combinatorial therapeutic activation with heparin and AICAR stimulates additive effects on utrophin A expression in dystrophic muscles. |
| Q34518069 | Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies |
| Q34994545 | Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. |
| Q28082625 | Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy |
| Q30378068 | DMD Mutations in 576 Dystrophinopathy Families: A Step Forward in Genotype-Phenotype Correlations |
| Q91338916 | Development of Novel Micro-dystrophins with Enhanced Functionality |
| Q38631895 | Dual AAV gene therapy for Duchenne muscular dystrophy with a 7-kb mini-dystrophin gene in the canine model |
| Q38087705 | Duchenne muscular dystrophy drug discovery - the application of utrophin promoter activation screening |
| Q81236528 | Dystonin/Bpag1--a link to what? |
| Q51979191 | Dystroglycan protein distribution coincides with basement membranes and muscle differentiation during mouse embryogenesis. |
| Q37335465 | Dystroglycan receptor is involved in integrin activation in intestinal epithelia |
| Q33930110 | Dystrophin isoform induction in vivo by antisense-mediated alternative splicing. |
| Q36960845 | Emerging strategies for cell and gene therapy of the muscular dystrophies |
| Q34873693 | Flow cytometry for the analysis of α-dystroglycan glycosylation in fibroblasts from patients with dystroglycanopathies |
| Q36295934 | Gene Therapy for Duchenne muscular dystrophy |
| Q34566454 | Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors |
| Q37767924 | Gene therapy for muscle disease |
| Q48006442 | Genotype-phenotype analysis in 2,405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase |
| Q28565042 | Identification of Dp71e, a new dystrophin with a novel carboxy-terminal end |
| Q35582583 | In vitro stability of therapeutically relevant, internally truncated dystrophins |
| Q36414153 | Inhibition of muscle fibrosis results in increases in both utrophin levels and the number of revertant myofibers in Duchenne muscular dystrophy. |
| Q24293583 | Interactions of intermediate filament protein synemin with dystrophin and utrophin |
| Q36691055 | L-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers |
| Q30486033 | Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice |
| Q40312569 | Mini-dystrophin efficiently incorporates into the dystrophin protein complex in living cells |
| Q59358387 | Molecular Therapies for Muscular Dystrophies |
| Q45885634 | Mutation spectrum leading to an attenuated phenotype in dystrophinopathies |
| Q90576641 | Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models |
| Q34567946 | Our trails and trials in the subsarcolemmal cytoskeleton network and muscular dystrophy researches in the dystrophin era |
| Q34575694 | Phosphorylation within the cysteine-rich region of dystrophin enhances its association with β-dystroglycan and identifies a potential novel therapeutic target for skeletal muscle wasting |
| Q37908904 | Progress in therapy for Duchenne muscular dystrophy. |
| Q35750055 | Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy |
| Q33891300 | Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin. |
| Q33342786 | Skeletal muscle-specific ablation of gamma(cyto)-actin does not exacerbate the mdx phenotype |
| Q36101284 | Spectrin, alpha-actinin, and dystrophin |
| Q34094400 | The ZZ domain of dystrophin in DMD: making sense of missense mutations. |
| Q40892634 | The carboxy-terminal third of dystrophin enhances actin binding activity |
| Q41820882 | The evolution of the dystroglycan complex, a major mediator of muscle integrity |
| Q101237580 | The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin |
| Q47606106 | The molecular cross talk of the dystrophin-glycoprotein complex. |
| Q33587381 | The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins |
| Q37629726 | The roles of the dystrophin-associated glycoprotein complex at the synapse |
| Q24319910 | The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module |
| Q37361308 | The synaptic CT carbohydrate modulates binding and expression of extracellular matrix proteins in skeletal muscle: Partial dependence on utrophin |
| Q41951688 | Thermodynamic stability, unfolding kinetics, and aggregation of the N-terminal actin-binding domains of utrophin and dystrophin. |
| Q54241942 | Variable rescue of microtubule and physiological phenotypes in mdx muscle expressing different miniaturized dystrophins. |
| Q35847178 | Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances |
| Q24672189 | ZZ domain of dystrophin and utrophin: topology and mapping of a beta-dystroglycan interaction site |
Search more.